Correlation Between Intestinal Microecology Imbalance and Stroke in Young Adults

Sponsor
Shanghai 6th People's Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05113043
Collaborator
(none)
60
2
19.9
30
1.5

Study Details

Study Description

Brief Summary

The relationship between the intestinal microecology and stroke has become a research hotspot in neurology field today. Maintaining the balance of the intestinal microbiota are expected to bring new breakthroughs for prevention and treatment of stroke. In recent years, stroke in young adults has an increasing incidence and a considerable socioeconomic impact because of high disability rate and health-care costs. So there is an urgent need to explore the role and mechanism of intestinal microecology imbalance in stroke, especially in the development and prognosis of stroke in young people. This study aims to use multi-omics technologies, including microbial diversity, metagenomics and metabonomics, to reveal the characteristics of intestinal flora in young stroke patients, identify biomarkers for predicting outcome after stroke and early detection of young people at high risk of stroke, and to further explore the role of gut-brain axis in the pathogenesis of stroke.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Research on Correlation Between Intestinal Microecology Imbalance and the Risk and Prognosis of Stroke in Young Adults
    Actual Study Start Date :
    Feb 1, 2022
    Anticipated Primary Completion Date :
    Jun 30, 2023
    Anticipated Study Completion Date :
    Sep 30, 2023

    Arms and Interventions

    Arm Intervention/Treatment
    Ischemic stroke

    Young patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.

    Hemorrhagic stroke

    Young patients who suffered from acute hemorrhagic stroke within 12 hours for the first time before entry into the study.

    Healthy Controls

    Healthy young people

    Outcome Measures

    Primary Outcome Measures

    1. Modified Rankin Scale scores [3 months]

      0 = No symptoms; 1 = No significant disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 = Moderate disability. Requires some help, but able to walk unassisted; 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 = Dead.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Clinical diagnosis of acute ischemic or hemorrhagic stroke

    • Admission within 12 hours

    • Aged 18-45 years

    Exclusion Criteria:
    • History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases

    • Combined with tumors, inflammatory bowel disease and other digestive system diseases

    • Combined with serious life-threatening diseases or condition

    • Any antibiotics, probiotics or prebiotic treatment within 3 months

    • Deteriorate and die before collecting faecal samples

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Shanghai 6th People's Hospital Shanghai China 200233
    2 Shanghai 6th People's Hospital Shanghai China 200233

    Sponsors and Collaborators

    • Shanghai 6th People's Hospital

    Investigators

    • Study Director: Lixia Xue, M.D., Ph.D., Shanghai 6th People's Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hao Chen, MD, Associate Clinical Professor, Shanghai 6th People's Hospital
    ClinicalTrials.gov Identifier:
    NCT05113043
    Other Study ID Numbers:
    • 2021-KY-112 (K)
    First Posted:
    Nov 9, 2021
    Last Update Posted:
    Feb 9, 2022
    Last Verified:
    Feb 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Hao Chen, MD, Associate Clinical Professor, Shanghai 6th People's Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 9, 2022